‘’Shift Towards DOACs from Traditional Therapies”
Across Europe, Direct Oral Anticoagulants are replacing traditional anticoagulants like warfarin and heparin due to their superior safety profiles, once-daily dosing, and minimal interaction requirements. European health agencies are revising formularies to include DOACs as first-line therapies. Digital adherence tools and home INR monitoring systems are enabling patients to maintain therapeutic outcomes without frequent hospital visits. Countries like France and the UK are leveraging real-world data to assess long-term DOAC effectiveness and safety, further accelerating their uptake in both hospital and outpatient settings.
